It's a tough one to explain. It's not possible for the company to have a lower value after FDA approval. A De-novo approval is not common and never guaranteed. Many get knocked back or delayed by more than a year.
I believe a larger holder is taking the opportunity to take profits now that stock interest is there after FDA approval. Remember 90% of stock is hands of top 20 shareholders.
My alternate theory is that stock is being manipulated/accumulated by an insto now that it has been de-risked. Pushing it lower to trigger retail sellers knowing that the top 20 are not sellers at these levels nor buyers given they hold considerable stock already.
I believe the end game for the big holders is selling to a competitor. That would be their best exit strategy.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.684M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 29583410 | 0.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.2¢ | 59394450 | 39 |
View Market Depth
| Last trade - 16.13pm 20/06/2025 (20 minute delay) ? |
| AXP (ASX) Chart |
Day chart unavailable